Form 4: Beam Therapeutics CEO John M. Evans Sells Shares and Acquires Stock Options
SEC Form 4 Filing
CEO John M. Evans of Beam Therapeutics sold shares of common stock and acquired stock options according to a recent SEC Form 4 filing.
Summary
- John M. Evans, CEO of Beam Therapeutics, reported transactions involving the company's common stock.
- On January 30, 2025, Evans sold 29,800 shares at a weighted average price of $26.7459 and 200 shares at $27.28.
- These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 14, 2024.
- Following these transactions, Evans directly owns 908,659 shares of Beam Therapeutics common stock.
- Evans also indirectly owns 103,000 shares through the John M. Evans, III 2018 Irrevocable Trust.
- Additionally, Evans acquired 155,000 stock options on January 31, 2025, with an exercise price of $25.92, vesting monthly over 48 months and expiring on January 31, 2035.
- After the transaction, Evans directly owns 155,000 stock options.
Sentiment
Score: 5
Explanation: The sentiment is neutral. The stock sales are offset by the acquisition of stock options, and the sales were conducted under a pre-arranged trading plan.
Positives
- The acquisition of 155,000 stock options indicates a continued alignment of Evans' interests with the long-term success of Beam Therapeutics.
Negatives
- The sale of 30,000 shares could be interpreted negatively by some investors, although it was conducted under a pre-arranged trading plan.
Risks
- Executive stock sales can sometimes create uncertainty among investors, even when conducted under pre-arranged plans.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies. Investors often monitor these transactions for insights into management's perspective on the company's future prospects. Rule 10b5-1 plans are frequently used to allow insiders to sell shares without raising concerns about insider trading.
Stakeholder Impact
- The stock sales may have a minor impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| June 14, 2024 | Date of adoption of Rule 10b5-1 trading plan |
| January 30, 2025 | Date of common stock sales |
| January 31, 2025 | Date of stock option acquisition |
| January 31, 2035 | Expiration date of stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.